Skip to main content

Table 2 Available patient and disease characteristics for patients with HCC potentially eligible for second-line therapy

From: Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

 

Subgroups #3 and #4

Subgroup #3a

Subgroup #4b

N

117

87

30

Sex, n (%)

 Men

100 (85)

75 (86)

25 (83)

 Women

17 (15)

12 (14)

5 (17)

Age, years

 Mean

71.87

71.52

72.90

Pre-existing confirmed diagnoses (ICD code)c, n (%)

 Hypertension (I10.x)

96 (83)

70 (81)

26 (53)

 Diabetes mellitus (E11, E14)

66 (56)

50 (58)

16 (53)

 Liver cirrhosis (K74.3, K74.4, K74.5, K74.6, K70.3, K71.7, P78.8)

62 (53)

45 (52)

17 (57)

 Liver cirrhosis and fibrosis (K74.x)

57 (49)

41 (47)

16 (53)

 Other liver diseases (K76.x)

46 (39)

30 (26)

16 (53)

 Disorders of lipoprotein metabolism and other lipidaemias (E78.x)

51 (44)

35 (40)

16 (53)

 Disorders of refraction and accommodation (H52.x)

46 (39)

31 (36)

15 (50)

 Obesity (E66.x)

39 (33)

26 (30)

13 (43)

 Dorsalgia (M54.x)

37 (32)

28 (32)

9 (23)

 Gastritis and duodenitis (K29.x)

35 (30)

28 (32)

7 (23)

 Chronic ischemic heart disease (I25.x)

36 (31)

26 (30)

10 (33)

 Disorders of purine and pyrimidine metabolism (E79.x)

32 (27)

24 (28)

8 (27)

 Cataract (H25.x)

26 (22)

19 (22)

7 (23)

Pre-existing medications (ATC code)c, n (%)

 β-blocking agents (C07A)

69 (59)

54 (62)

15 (50)

 Loop diuretics (C03C)

45 (38)

36 (41)

9 (30)

 ACE inhibitors, plain (not in combination) (C09A)

45 (38)

31 (36)

14 (47)

 Lipid-modifying agents, plain (C10A)

33 (28)

21 (24)

12 (40)

 Antithrombotic agents (B01A)

33 (28)

24 (28)

9 (30)

 Agents for peptic ulcer and gastro-oesophageal reflux disease (A02B)

64 (55)

46 (53)

18 (60)

 Anti-inflammatory and antirheumatic products, non-steroids (M01A)d

42 (36)

31 (36)

11 (37)

 Other analgesics and antipyretics (N02B)

35 (30)

26 (30)

9 (30)

 Opioids (N02A)

17 (15)

15 (17)

2 (7)

 Antibacterials for systemic use (J01)e

41 (35)

30 (34)

11 (37)

 Diagnostic agents (V04B, V04C)

33 (28)

25 (29)

8 (27)

 Anti-gout preparations (M04A)

31 (26)

23 (26)

8 (27)

 Antidiabetes medications, excl. insulins (A10B)

29 (25)

22 (25)

7 (23)

Patients who received chemotherapy prescriptionsf (L01)

2 (2)

1 (1)

1 (3)

Mean duration of sorafenib therapy, days

 

223.6

230.0

 Standard deviation

 

307.3

376.0

 Range

 

28–1630

28–1972

  1. ACE angiotensin-converting enzyme, ATC anatomical therapeutic chemical, ICD International Classification of Diseases
  2. aPatients who died during the observation period but not on sorafenib therapy (i.e. more than 70 days between the last sorafenib prescription and death)
  3. bPatients who were still alive at the end of the observation period and at least 70 days had passed between the last prescription of sorafenib and the end of the observation period
  4. cDuring the year prior to sorafenib therapy (diagnoses during the quarter in which patients were identified were not included but those of prior quarters were); reported by at least 20% of patients in at least two of the three groups (study population, subgroup #3, subgroup #4), with the exception of opioids, which were an important contributor to the analgesic category
  5. dValue may be underestimated because many of these medications are available without prescription (i.e. over the counter)
  6. ePatients may have received more than one cycle of treatment with antibiotics
  7. fDuring the year prior to sorafenib therapy
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us